Articles tagged with Attention Deficit Hyperactivity Disorder
Researchers at John Carroll University have developed blue-blocking glasses that block blue light to reduce ADHD symptoms and improve sleep patterns. The glasses work by advancing the circadian rhythm, leading to a marked decline in ADHD symptoms and promoting better sleep.
A national survey of parents with children aged 6-17 found that 60% reported their child's medication stopped working before 6 p.m. This suggests a need for reassessment of treatment duration and potential factors contributing to the perceived ineffectiveness.
A study of psychiatrists and parents found significant differences in perceptions of pediatric ADHD and psychiatric comorbidities. The researchers suggest that improving communication between psychiatrists, parents, and patients can lead to better treatment outcomes for children with complicated ADHD.
The NIEHS has awarded grants totaling $3.5 million to seven outstanding young environmental scientists. These researchers will investigate the mechanisms of environmental exposures and human biology, human pathophysiology, and human disease.
Researchers found that insulin levels affect dopamine systems in the brain, which are involved in drug addiction and neuropsychiatric conditions. In diabetic animals, amphetamine-induced dopamine signaling was disrupted, suggesting a link between insulin status and brain function.
Research suggests that computerized working memory training can improve executive functioning and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children. This innovative approach offers a promising therapeutic strategy for alleviating the condition's impact on daily functioning.
A Mayo Clinic study of nearly 5,000 children with ADHD found that treatment with prescription stimulants was associated with improved long-term academic success. The study also showed that girls with untreated ADHD were equally vulnerable to poor school outcomes as boys and may be at risk for being undertreated.
A new study reveals that Pycnogenol, an antioxidant plant extract, lowers ADHD symptoms in children by reducing stress hormones. The findings suggest a significant stress hormone-lowering effect for a nutritional supplement, providing hope for parents seeking alternative treatments.
Research estimates that approximately 8.7 percent of U.S. children between the ages of 8 and 15 have attention-deficit/hyperactivity disorder (ADHD). Despite this prevalence, only a minority of affected children receive consistent treatment with ADHD medications.
A five-year study led by Lehigh University's College of Education identified effective nonmedicinal strategies to decrease aggressiveness and improve behavior in preschoolers with ADHD. The 'Project Achieve' study showed a 17-percent decrease in aggression and a 21-percent improvement in social skills for parents, while teachers saw a ...
Adults with ADHD show blunted response to methylphenidate, suggesting dopamine dysfunction may contribute to ADHD symptoms. Reduced dopamine activity is also associated with increased substance abuse in individuals with ADHD.
A study found a gene variant associated with thinner brain tissue in areas handling attention, but also better clinical outcomes among individuals with ADHD. The 7-repeat form of the dopamine D4 receptor gene was linked to improved symptoms and regained brain thickness in affected individuals.
A specific gene variant associated with attention deficit hyperactivity disorder (ADHD) may also predict better clinical outcomes and higher IQ in teens. The variant, called the 7-repeat version of the dopamine D4 receptor gene, is linked to thinner brain areas controlling attention but confers advantage only among youth with ADHD.
A new study published in SLEEP journal shows that methylphenidate (MPH) significantly improves vigilance performance in children with ADHD who have poor sleep efficiency. The researchers tested 37 children aged 6-12 and found a moderate increase in arousal levels, facilitating improved performance.
A study published in the Journal of Attention Disorders found that treatment rates for ADHD have increased rapidly across all age groups, with females showing the greatest increase. Improved diagnosis and changes in medication types contributed to this growth.
A new study by Dr. Lisa Strohschein found a significantly higher risk of Ritalin use among children whose parents divorce compared to those whose parents stay together. The research suggests that parental divorce may act as a stressful life event, leading to adjustment problems and increased ADHD symptoms.
A follow-up study found that pediatricians' behavioral health treatment methods showed only partial success, despite receiving structured interventions, FDA warnings, and mental health reforms. The interventions, including newsletters and resource guides, aimed to increase education on anxiety and depression recognition, collaboration ...
Long-term treatment with VYVANSE shows significant efficacy in ADHD, with 95% of children experiencing overall improvement after 12 months. The study also found consistent time to maximum concentration of d-amphetamine from patient to patient.
Daytrana demonstrated significant improvements in symptom control, tolerability, and safety in children with ADHD over a 12-month period. The study showed effective treatment of ADHD symptoms, with 83% and 78% of parents reporting 'very much improved' or 'much improved' outcomes.
A recent study found that guanfacine extended release significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years. The investigational nonstimulant medication demonstrated clinically meaningful efficacy for up to 24 months of treatment.
A double-blind study found DAYTRANA significantly reduced ADHD symptoms in boys and girls aged 6-12 by 56.5% and 57.4%, respectively. The patch offers a favorable safety profile and provides a platform to discuss gender differences in ADHD treatment.
Long-term study results show that LIALDA (mesalamine) is effective in maintaining remission and preventing relapse in patients with mild to moderate ulcerative colitis. Nearly 9 out of 10 patients on once-daily LIALDA remained relapse free at the end of 12 months.
A study found children with both autism and ADHD are four times more likely to bully than their peers, highlighting the need for additional support services.
A study investigates the impact of methylphenidate on young ADHD drivers' ability to focus while navigating real-world distractions. The research team aims to determine if controlled-release stimulant medication improves driving performance in such situations.
Researchers discovered a molecular mechanism that strengthens brain networks by closing ion channels, which may improve working memory and reduce distractibility in conditions like ADHD. This discovery has implications for developing drug therapies for normal aging and treating cognitive changes in schizophrenia and bipolar disorder.
Researchers at Yale University have discovered a molecular mechanism that dynamically alters brain network connections, influencing working memory and cognitive function. Closing ion channels can strengthen connectivity, improving working memory and reducing distractibility.
Research suggests that children with attention deficit hyperactivity disorder (ADHD) are more likely to develop alcohol problems, particularly those who experience heavy drinking and stress in childhood. Parental alcoholism and family dynamics also play a significant role in the development of alcohol use disorders among young adults.
A study published in the Journal of Clinical Sleep Medicine finds that adolescents with sleep disturbances are more likely to receive bad grades, experiencing symptoms such as restless legs, difficulty concentrating, and snoring. Parents and teens can improve school performance by following recommended sleep habits.
The FDA has approved LIALDA (mesalamine), the first oral once-daily mesalamine for patients with active, mild to moderate ulcerative colitis. Clinical trials found LIALDA effective in inducing remission compared to placebo after eight weeks of treatment.
A recent study by Vanderbilt University Medical Center researchers found that prenatal cocaine exposure in rabbits causes a long-lasting displacement of dopamine receptors in certain brain cells. This effect alters their ability to function normally and may lead to subtle cognitive impairments, attention deficits, and emotional problems.
Researchers found lower levels of dopamine transporters in certain brain regions of ADHD patients compared to controls. ADHD patients experienced higher levels of inattention despite similar dopamine transporter levels, indicating a complex relationship between dopamine and attention.
New data shows significant improvement in core symptoms of ADHD with guanfacine extended release, including hyperactivity, impulsivity, and inattention. The medication was well-tolerated with mild or moderate side effects.
A phase I clinical trial found that Shire's investigational drug SPD465 was bioequivalent to a combination of ADDERALL XR and mixed amphetamine salts immediate release. This suggests that SPD465 could offer full-day symptom control for adults with ADHD, potentially eliminating the need for augmenting long-acting stimulant medications.
A 25-year meta-analysis of 29 double-blind studies involving nearly 4,500 children with ADHD found that stimulant medications produced larger effect sizes than non-stimulants. The study suggests that amphetamine- and methylphenidate-based stimulants are more effective treatments for ADHD symptoms.
The investigational amphetamine compound SPD465 demonstrated improved Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in adults for up to 16 hours post-dose. The study results showed that SPD465 provided significant improvement in ADHD symptom control based on PERMP and ADHD-RS scores.
A phase 3 study demonstrated lisdexamfetamine dimesylate's effectiveness in reducing ADHD symptoms, with 95% of children showing significant improvement. The medication was well-tolerated, with side effects similar to those of marketed ADHD stimulants.
A study found that adults with depressive disorder, Bipolar Disorder, or anxiety disorder are at risk of having undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), with 32.0% comorbid in those with depression and 21.2% in those with bipolar disorder. Researchers analyzed medical claims data to identify this comorbidity.
The DAYTRANA patch offers flexible wear times, allowing physicians to manage ADHD symptoms and minimize late-day side effects. The patch demonstrated significant efficacy in reducing ADHD symptoms, even when worn for shorter periods.
A new study finds methylphenidate, a widely prescribed ADHD drug, to be safe and effective in preschoolers when used at low doses. However, younger children may experience slower growth rates and side effects such as irritability and weight loss.
A long-term study found that preschoolers with ADHD benefit from low doses of methylphenidate, but may need higher doses later on to maintain effectiveness. The study also showed significant side effects, including growth rate changes and weight loss.
Children with attention-deficit/hyperactivity disorder (ADHD) experience increased healthcare costs in the two years before and after diagnosis compared to those without ADHD. White children have higher expenses than other ethnicities, reflecting a possible cultural factor in treatment acceptance.
A study by researchers at the University of Virginia Health System found that OROS methylphenidate (Concerta) improves driving performance in teen drivers with ADHD, reducing inattentive and hyperactive errors. The study suggests Concerta should be the initial treatment for teens with ADHD.
Katie Lee Joel joins forces with experts to promote low-phosphorus cooking, sharing six new recipes to honor her grandfather's memory and help patients manage chronic kidney disease. The Kidney Friendly Comfort Foods program aims to show that kidney-friendly foods don't have to be boring.
Researchers at Washington University School of Medicine found that nearly half of children with attention-deficit/hyperactivity disorder (ADHD) are not receiving treatment. The study, which analyzed data from over 1,600 twins, suggests that many cases of ADHD may be underdiagnosed or undertreated.
Researchers have improved screening for Attention Deficit-Hyperactivity Disorder (ADHD) among substance users, enabling timely treatment and better recovery from addiction. The study uses the Conners Adult ADHD Rating Scale (CAARS) to facilitate accurate diagnosis and targeted interventions.
Three studies presented at CPDD show lisdexamfetamine dimesylate has lower euphoric effects and delayed peak effects compared to d-amphetamine sulfate. Lisdexamfetamine dimesylate also produces liking effects in healthy adults with previous history of stimulant abuse.
A new study reveals that ADHD medications mainly affect the prefrontal cortex, a region linked to attention and decision-making. This finding could aid in developing more effective treatments.
A new study reveals that Pycnogenol, a French maritime pine bark extract, significantly reduces hyperactivity and improves attention, concentration, and motor-visual coordination in children with ADHD. The study's findings suggest that Pycnogenol may serve as a safe and effective treatment for children diagnosed with ADHD.
Researchers have found that an ADHD medication 'harmonizes' with the body's dopamine system, improving attention and focus in individuals. The study, presented at a medical conference, provides direct evidence of the drug's beneficial effect, which was previously speculative.
Researchers found that Ritalin increases norepinephrine and suppresses sensory responses in the brain, allowing individuals to focus better. The study provides insights into how the drug produces its paradoxical effects and may lead to more effective treatments for ADHD.
Long-acting mixed amphetamine salts (MAS XR) and immediate-release mixed amphetamine salts showed similar efficacy to short- or long-acting methylphenidates. Stimulant medications like amphetamines and methylphenidate are more effective in treating ADHD symptoms, according to the study.
Phase II and phase III clinical trials demonstrate DAYTRANA's effectiveness in reducing ADHD symptoms, including improvements in behavior and classroom performance. The patch formulation provides a once-daily treatment option for children aged 6-12 with ADHD.
A neurocognitive study found that mixed amphetamine salts extended release improved divided attention, visuospatial working memory, visual scanning, and mental flexibility in adults with ADHD. Participants who received the medication showed significant improvements in response speed and maintained accuracy when switched to placebo.
A phase II trial of NRP104 demonstrated a statistically significant reduction in ADHD symptoms comparable to mixed amphetamine salts extended-release. The medication was well-tolerated and showed improved behavior, academic productivity, and reduced symptoms in children aged 6 to 12 years with ADHD.
A new study found that lead exposure affects executive function in children with ADHD, particularly those with certain genetic variations. The research suggests that boys are more vulnerable to the negative effects of lead exposure on attentional flexibility.
Researchers found that individuals with ADHD were more likely to misuse their medication, particularly selling or taking too much. Immediate release stimulants were most prone to misuse, while extended release formulations were not targeted by abusers.
Researchers found that children with ADHD or conduct disorder display more extreme personality profiles, including aggressiveness and thrill-seeking behavior. The study suggests a strong connection between personality traits and these disorders, highlighting the importance of considering personality in initial assessments.
A study compared the abuse potential of two methylphenidate formulations, finding that the delayed-release version took longer to produce maximum effects and was less detectable. Researchers suggest that different formulations may vary in safety characteristics, warranting further study.
A study by Queen's University psychologist Mark Sabbagh found that Chinese preschoolers show better self-control than their North American counterparts. Executive functioning skills, which enable focus on goals despite distractions, develop more rapidly in Chinese children.
The investigational methylphenidate transdermal system (MTS) demonstrated statistically significant reductions in ADHD symptoms and was well-tolerated in patients aged 6 to 12. MTS improved behavior, math performance, and overall symptom reduction compared to placebo.